BRCA Single Gene denied as experimental or investigational by Aetna?
An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for brca single gene are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on BRCA Single Gene
## Why Aetna May Deny BRCA Single-Gene Testing as Experimental
Aetna's clinical policies classify certain genetic tests as experimental or investigational when the plan determines that sufficient evidence does not yet support their use for the submitted clinical indication. For BRCA single-gene testing, this denial is most commonly applied to newer or less-established clinical contexts — such as testing for a specific variant class, a particular tumor type, or a therapeutic-selection indication that Aetna's policy has not yet deemed proven. It is less common for established hereditary breast and ovarian cancer risk indications, where consensus guidelines and payer policies broadly support testing.
## Federal Appeal Rights
Experimental denials must still comply with ACA §2719 internal-appeal and external-review requirements for non-ERISA plans, and with ERISA §503 for self-funded plans. Crucially, independent IRO reviewers apply their own evidence assessment — they are not bound by Aetna's internal policy — which is why external review overturns experimental denials at a meaningful rate. File for external review within four months of the final internal denial. Expedited review is available when the treatment or diagnostic decision is urgent.
## Appeal Process and Timeline
1. Request Aetna's written policy (Clinical Policy Bulletin) defining the experimental classification and the evidence standard it applies. 2. Identify the specific indication Aetna treats as experimental versus the indication your clinician ordered the test for — these may not match. 3. File the internal appeal with peer-reviewed literature and guideline citations supporting clinical validity for your indication. 4. Escalate to external review if the internal appeal fails; IROs weigh clinical evidence independently.
## Documentation to Gather
- Ordering clinician or genetic counselor letter: a detailed statement explaining the clinical question, the specific indication, and why BRCA single-gene testing is the appropriate diagnostic approach for this patient.
- Clinical indication records: oncology, pathology, and genetic counseling notes establishing personal and family history, diagnosis, and the clinical decision this test is intended to inform.
- Peer-reviewed literature: published studies supporting clinical utility for the specific indication; cite guideline organizations (e.g., NCCN, ASCO, USPSTF) generically without quoting specific numbers.
- Pathology and diagnostic records: tumor type, stage, and receptor status if the test is for treatment selection.
## Criteria-Mapping Strategy
Obtain Aetna's Genetic Testing Clinical Policy Bulletin for BRCA testing and its stated evidence criteria. Map each criterion to a piece of peer-reviewed or guideline-supported evidence and to the clinical record. External IRO reviewers applying independent evidence standards often reach different conclusions than Aetna's internal reviewers — presenting a well-organized evidence package substantially improves the likelihood of reversal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →